Deutsche Bank Comments On Gilead Sciences Client Dinner

According to Deutsche Bank, it met with Gilead Sciences GILD management. Deutsche Bank said that it hosted a client dinner with COO John Milligan last night. “Co sees B-tripla as potentially being the "kindler gentler Atripla," with potential for uptake where Sustiva is not preferred. According to the Gilead, there may be 3-4% of centers (clustered) where Sustiva isn't preferred, as well as other populations (African American, women of child-bearing age) where Sustiva is not used. These might be earlier adopters of B-tripla use, converting current Truvada based patients to B-tripla (better economics for Gilead) . The co believes QUAD will be viewed as more robust and take share from Atripla. Net/net combined - both could grow Gilead HIV sales from uptake in different market segments.” Gilead Sciences closed yesterday at $40.68.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsBiotechnologyDeutsche BankGilead SciencesHealth CareJohn Milligan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!